

Peter E Penson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/843671/publications.pdf>

Version: 2024-02-01

111
papers

2,517
citations

186265

28
h-index

243625

44
g-index

113
all docs

113
docs citations

113
times ranked

3167
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies. Archives of Medical Science, 2023, 19, 1214-1227.	0.9	2
2	The interaction of Helicobacter pylori with cancer immunomodulatory stromal cells: New insight into gastric cancer pathogenesis. Seminars in Cancer Biology, 2022, 86, 951-959.	9.6	22
3	Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. British Journal of Clinical Pharmacology, 2022, 88, 1520-1528.	2.4	17
4	Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia. European Journal of Preventive Cardiology, 2022, 29, 718-720.	1.8	5
5	Extreme cardiovascular risk—do we need a new risk category?. European Heart Journal, 2022, 43, 1784-1786.	2.2	11
6	Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observational, cross-sectional study. Rheumatology International, 2022, 42, 261-271.	3.0	5
7	Prevalence of statin intolerance: a meta-analysis. European Heart Journal, 2022, 43, 3213-3223.	2.2	151
8	Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress. Biomarker Insights, 2022, 17, 117727192110667.	2.5	1
9	Homozygous familial hypercholesterolaemia: shedding new light on a rare but deadly condition. European Journal of Preventive Cardiology, 2022, 29, 815-816.	1.8	1
10	Warfarin—Is Self-Care the Best Care?. Thrombosis and Haemostasis, 2022, 122, 471-474.	3.4	2
11	Step-by-step diagnosis and management of the nocebo/drugcebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP). Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1596-1622.	7.3	35
12	Supermarket/Hypermarket Opportunistic Screening for Atrial Fibrillation (SHOPS-AF): A Mixed Methods Feasibility Study Protocol. Journal of Personalized Medicine, 2022, 12, 578.	2.5	3
13	Lifetime serum concentration of 25-hydroxyvitamin D 25(OH) is associated with hand grip strengths: insight from a Mendelian randomisation. Age and Ageing, 2022, 51, .	1.6	4
14	Curcumin - The Nutraceutical With Pleiotropic Effects? Which Cardiometabolic Subjects Might Benefit the Most?. Frontiers in Nutrition, 2022, 9, .	3.7	12
15	Assessment of asthma management in adult patients: A retrospective case-note review in a general practice. British Journal of Pharmacy, 2022, 7, .	0.3	0
16	The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). Clinical Nutrition, 2021, 40, 255-276.	5.0	75
17	Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes. Atherosclerosis, 2021, 316, 58-65.	0.8	26
18	Lipid-lowering therapies: Better together. Atherosclerosis, 2021, 320, 86-88.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Drucebo effect – the challenge we should all definitely face!. Archives of Medical Science, 2021, 17, 542-543.	0.9	13
20	Exploring pharmacists’s™ views surrounding conscientious objection to abortion and implications in practice. International Journal of Pharmacy Practice, 2021, 29, 258-264.	0.6	6
21	Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP). Pharmacological Research, 2021, 166, 105499.	7.1	62
22	Colchicine and Cardiovascular Outcomes: a Critical Appraisal of Recent Studies. Current Atherosclerosis Reports, 2021, 23, 32.	4.8	11
23	Nocebo/drucebo effect in statin-intolerant patients: an attempt at recommendations. European Heart Journal, 2021, 42, 4787-4788.	2.2	27
24	Potential Benefits of Phytochemicals for Abdominal Aortic Aneurysm. Current Medicinal Chemistry, 2021, 28, 8595-8607.	2.4	14
25	Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases – A position paper from the International Lipid Expert Panel (ILEP). Progress in Cardiovascular Diseases, 2021, 67, 40-52.	3.1	39
26	Effects of statins on myocarditis: A review of underlying molecular mechanisms. Progress in Cardiovascular Diseases, 2021, 67, 53-64.	3.1	23
27	Postmarketing nutravigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. Archives of Medical Science, 2021, 17, 856-863.	0.9	19
28	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. Progress in Cardiovascular Diseases, 2021, 67, 65-74.	3.1	23
29	Statins as anti-pyoptotic agents. Archives of Medical Science, 2021, 17, 1414-1417.	0.9	31
30	Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective. Metabolites, 2021, 11, 611.	2.9	5
31	Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry. Atherosclerosis, 2021, 333, 16-23.	0.8	19
32	Secondary Stroke Prevention in Polish Adults: Results from the LIPIDOGRAM2015 Study. Journal of Clinical Medicine, 2021, 10, 4472.	2.4	2
33	RNA Silencing in the Management of Dyslipidemias. Current Atherosclerosis Reports, 2021, 23, 69.	4.8	19
34	Clinical Features of Familial Hypercholesterolemia in Children and Adults in EAS-FHSC Regional Center for Rare Diseases in Poland. Journal of Clinical Medicine, 2021, 10, 4302.	2.4	10
35	Bacterial lipopolysaccharide’s–Stoking the fire of residual risk?. Trends in Cardiovascular Medicine, 2021, , .	4.9	0
36	The management of asthma in adult patients in the community pharmacy setting: Literature review. Research in Social and Administrative Pharmacy, 2021, 17, 1893-1906.	3.0	3

#	ARTICLE	IF	CITATIONS
37	Management of Statin Intolerance. <i>Contemporary Cardiology</i> , 2021, , 207-218.	0.1	0
38	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, .	4.1	1
39	The prevalence of statin intolerance worldwide: a systematic review and meta-analysis with 4,143,517 patients. <i>European Heart Journal</i> , 2021, 42, .	2.2	3
40	The Differences in the Prevalence of Cardiovascular Disease, Its Risk Factors, and Achievement of Therapeutic Goals among Urban and Rural Primary Care Patients in Poland: Results from the LIPIDOGRAM 2015 Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 5656.	2.4	9
41	A Systematic Review of Published Physiologically-based Kinetic Models and an Assessment of their Chemical Space Coverage. <i>ATLA Alternatives To Laboratory Animals</i> , 2021, 49, 197-208.	1.0	20
42	Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice. <i>Nutrients</i> , 2021, 13, 2957.	4.1	9
43	CRISPR Gene Editing in Lipid Disorders and Atherosclerosis: Mechanisms and Opportunities. <i>Metabolites</i> , 2021, 11, 857.	2.9	8
44	Statins and Lp(a): do not make perfect the enemy of excellent. <i>European Heart Journal</i> , 2020, 41, 190-191.	2.2	15
45	A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. <i>Drug Discovery Today</i> , 2020, 25, 58-72.	6.4	27
46	Genetic testing in familial hypercholesterolaemia: What does it add?. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 105-106.	1.8	9
47	Inclisiran – New hope in the management of lipid disorders?. <i>Journal of Clinical Lipidology</i> , 2020, 14, 16-27.	1.5	80
48	Commentary: Statins, COVID-19, and coronary artery disease: killing two birds with one stone. <i>Metabolism: Clinical and Experimental</i> , 2020, 113, 154375.	3.4	40
49	LDL-C: lower is better for longer – even at low risk. <i>BMC Medicine</i> , 2020, 18, 320.	5.5	78
50	Comparison of LDL-C calculation by friedewald and martin/hopkins methods in 12,243 adults from the United States of America. <i>European Heart Journal</i> , 2020, 41, .	2.2	3
51	Vernakalant hydrochloride for the treatment of atrial fibrillation: evaluation of its place in clinical practice. <i>Future Cardiology</i> , 2020, 16, 585-595.	1.2	1
52	The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia. <i>Current Atherosclerosis Reports</i> , 2020, 22, 67.	4.8	15
53	Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. <i>Pharmacological Research</i> , 2020, 158, 104891.	7.1	62
54	Spotlight Commentary: What's new in lipid-lowering pharmacology? Integrating basic and clinical research to improve patient outcomes. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2111-2113.	2.4	2

#	ARTICLE	IF	CITATIONS
55	Epigenetic control of atherosclerosis via DNA methylation: A new therapeutic target?. Life Sciences, 2020, 253, 117682.	4.3	9
56	Application of PLGA nano/microparticle delivery systems for immunomodulation and prevention of allotransplant rejection. Expert Opinion on Drug Delivery, 2020, 17, 767-780.	5.0	17
57	Statin therapy in athletes and patients performing regular intense exercise – Position paper from the International Lipid Expert Panel (ILEP). Pharmacological Research, 2020, 155, 104719.	7.1	17
58	What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?. Progress in Cardiovascular Diseases, 2020, 63, 219-227.	3.1	35
59	Intake of Caffeine and Its Association with Physical and Mental Health Status among University Students in Bahrain. Foods, 2020, 9, 473.	4.3	36
60	Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,164,029 participants. Clinical Nutrition, 2020, 39, 3677-3686.	5.0	52
61	Statins and LDL-C in Secondary Prevention – So Much Progress, So Far to Go. JAMA Network Open, 2020, 3, e2025675.	5.9	27
62	Vitamin D and SAMS. Contemporary Cardiology, 2020, , 121-128.	0.1	3
63	Liposome Circulation Time is Prolonged by CD47 Coating. Protein and Peptide Letters, 2020, 27, 1029-1037.	0.9	16
64	Recent advancements in liposome-based strategies for effective drug delivery to the brain. Current Medicinal Chemistry, 2020, 28, 4152-4171.	2.4	7
65	Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovascular Research, 2019, 115, 204-212.	3.8	34
66	The Role of Protein SUMOylation in the Pathogenesis of Atherosclerosis. Journal of Clinical Medicine, 2019, 8, 1856.	2.4	27
67	Warfarin Therapy and Improved Anticoagulation Control by Patient Self-Management. Thrombosis and Haemostasis, 2019, 119, 1550-1552.	3.4	2
68	Regulatory T cells: Possible mediators for the anti-inflammatory action of statins. Pharmacological Research, 2019, 149, 104469.	7.1	32
69	Worldwide Dyslipidemia Guidelines. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	17
70	Associations between the lipid profile and the development of hypertension in young individuals – the preliminary study. Archives of Medical Science, 2019, 18, 25-35.	0.9	4
71	Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. Journal of Clinical Medicine, 2019, 8, 2051.	2.4	60
72	Effects of carbohydrate-restricted diets on low-density lipoprotein cholesterol levels in overweight and obese adults: a systematic review and meta-analysis. Nutrition Reviews, 2019, 77, 161-180.	5.8	71

#	ARTICLE	IF	CITATIONS
73	What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?. <i>Cardiovascular Research</i> , 2019, 115, e26-e31.	3.8	46
74	Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 1706-1714.	10.3	18
75	P3836The prognostic accuracy of bleeding risk prediction scores in patients with atrial fibrillation: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2018, 39, .	2.2	0
76	P5086Associations between very low concentrations of LDL-Cholesterol, hsCRP and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, .	2.2	1
77	Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1857-1865.	1.8	16
78	Introducing the "Drucebo"™ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 1023-1033.	7.3	84
79	Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study. <i>European Heart Journal</i> , 2018, 39, 3641-3653.	2.2	69
80	Evaluating bempedoic acid for the treatment of hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 251-259.	4.1	40
81	Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2017, 11, 617-623.	1.5	19
82	Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 972-985.e9.	1.5	40
83	The Effects of Tamoxifen on Plasma Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. <i>Drugs</i> , 2017, 77, 1187-1197.	10.9	29
84	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2017, 122, 105-117.	7.1	21
85	Autonomic and Autacoid Pharmacology: Goodbye and thank you. <i>Autonomic and Autacoid Pharmacology</i> , 2017, 37, 51-51.	0.5	0
86	The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. <i>Atherosclerosis</i> , 2017, 265, 275-282.	0.8	144
87	The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. <i>Journal of Clinical Lipidology</i> , 2017, 11, 1393-1406.	1.5	60
88	220...Daphnia magna as a model for quantifying chaos in cardiac arrhythmia. <i>Heart</i> , 2017, 103, A143.2-A143.	2.9	4
89	P627Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
90	3104Associations between cardiovascular disease, cancer and very low hdl cholesterol in the reasons for geographical and racial differences in stroke (REGARDS) study. <i>European Heart Journal</i> , 2017, 38, .	2.2	0

#	ARTICLE	IF	CITATIONS
91	The role of nutraceuticals in the prevention of cardiovascular disease. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S21-S31.	1.7	81
92	3100Effects of morning versus evening statin therapy on lipid profile: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2017, 38, .	2.2	0
93	Association between telomere length and complete blood count in US adults. <i>Archives of Medical Science</i> , 2017, 3, 601-605.	0.9	30
94	Lipoprotein(a) and the risk of atrial fibrillation “ is there a link. <i>Heart Beat Journal</i> , 2017, 2, 49-50.	0.2	0
95	Autonomic & Autacoid Pharmacology 2016: The year in review. <i>Autonomic and Autacoid Pharmacology</i> , 2016, 36, 27-27.	0.5	1
96	Effects of pentoxifylline on inflammatory markers and blood pressure. <i>Journal of Hypertension</i> , 2016, 34, 2318-2329.	0.5	31
97	Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2016, 107, 360-371.	7.1	61
98	Bioresorbable scaffold “ A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	1.7	24
99	Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases “ Some answers and still many questions. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 370-378.	6.1	41
100	Sunday 28 August 2016. <i>European Heart Journal</i> , 2016, 37, 191-598.	2.2	9
101	Monday 29 August 2016. <i>European Heart Journal</i> , 2016, 37, 599-983.	2.2	6
102	D-003 (<i>Saccharum officinarum</i>): The forgotten lipid-lowering agent. <i>Pharmacological Research</i> , 2016, 114, 42-46.	7.1	5
103	<i>Autonomic & Autacoid Pharmacology</i> : past, present and future. <i>Autonomic and Autacoid Pharmacology</i> , 2015, 35, 45-45.	0.5	3
104	Lecturing: A lost art. <i>Currents in Pharmacy Teaching and Learning</i> , 2012, 4, 72-76.	1.0	10
105	Synthesis of antagonists of muscarinic (M3) receptors. <i>Collection of Czechoslovak Chemical Communications</i> , 2011, 76, 781-801.	1.0	2
106	Incense “ A problematic method of drug-delivery. <i>Medical Hypotheses</i> , 2009, 72, 482.	1.5	0
107	Activation of β^2 -adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2008, 378, 589-597.	3.0	10
108	Protective role of β^2 - and β^3 -adrenoceptors at reperfusion in isolated rat heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 719.	1.9	1

#	ARTICLE	IF	CITATIONS
109	Vasopressors for cardiopulmonary resuscitation. , 2007, 115, 37-55.		19
110	Effects of hypoxia on the vasodilator activity of nifedipine and evidence of secondary pharmacological properties. European Journal of Pharmacology, 2006, 536, 279-286.	3.5	2
111	The roles of alpha- and beta-adrenoceptor stimulation in myocardial ischaemia. Autonomic and Autacoid Pharmacology, 2004, 24, 87-93.	0.5	19